[1] |
FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong.
Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
|
[2] |
WANG Shan, XIE Bo, LIU Huimin, LI Zhihao.
Adverse event signals for celecoxib based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
|
[3] |
LI Yingfen, HAN Lei.
Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
|
[4] |
CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili.
One case of severe liver injury caused by Tianma Shouwu tablets
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
|
[5] |
ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie.
Adverse reaction monitoring of toothpaste in China under the new regulatory system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
|
[6] |
WANG Xin, SHI Leilei, ZHANG Yuhan, XIE Yundong, LIU Jiping.
The role of MRPs transporters in drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 229-234.
|
[7] |
GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe.
Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
|
[8] |
GAO Yuan, SHI Wei, XIAO Xiaohe, BAI Zhaofang, WANG Jiabo.
Research progress on the animal models of idiosyncratic drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 33-39.
|
[9] |
LI Shuran, GUO Shanshan, JI Zuen, ZHANG Wei, CUI Xiaolan.
Research status of cognitive dysfunction after SARS-CoV-2 infection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 59-64.
|
[10] |
ZHANG Liangliang, HU Changkun, WU Zekun, ZHOU Wei, LIAO Zebin, GAO Yue.
Protective effect and mechanism of dimethyl fumarate against intestinal radiation injury
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 83-88.
|
[11] |
LIU Min, CHEN Yan, LIU Wendong, WANG Haixue.
Updates and reflections on expedited reporting of safety information during drug clinical trials
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
|
[12] |
BUCHANAN James.
Assessment of drug-induced liver injury via nR modified Hy’s law and PALT
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 117-120.
|
[13] |
LI Xingren, SHEN Aizong, SU Dan.
Evaluation of the rationality of proton pump inhibitors in preventing perioperative stress related mucosal disease in biliary and pancreatic surgery
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1022-1026.
|
[14] |
YU Hongli, YU Dongmei, XIAO Aili, ZHU Lan, SONG Haibo.
Risks of safety Qingkailing oral preparation
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1046-1048.
|
[15] |
LI Jing, XU Ye, LIU Ranjia, PAN Chen, CUI Xiangli.
Adverse reactions in patients with COVID-19 after using tocilizumab
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1049-1053.
|